As immunology and neuroscience experts, we work with clients to discover new targets and develop treatments for cancer, autoimmune diseases such as multiple sclerosis, liver fibrosis and neurodegenerative diseases.
Please get in touch for further information on our service offerings and possibilities.
A hallmark of cancer is its characteristic immunosuppressive immune environment.
We can design specialised assays and programs of work to understand immune function in the tumour microenvironment and how this might be manipulated therapeutically by either antibodies, small molecules or combinations of these. Assays are validated with benchmark controls.
We have world-leading expertise in research into multiple sclerosis (MS), a disease that requires understanding of immunology, inflammation and neuroscience.
Aquila can provide end-to-end support for MS drug discovery. We offer a suite of in vitro assays for clients seeking to reduce disease progression in MS by improving remyelination efficiency. These include an Oligodendrocyte Precursor Cell (OPC) culture assay to assess the effects of a test substance on differentiation and cell survival.
Following compound screening in our OPC assay, your lead compound can be progressed to our Central Nervous System (CNS) slice model to assess functional remyelination efficiency following toxin-induced demyelination. This model is a powerful screening tool for potential translational tool linking in vitro assays and in vivo studies.
Our range of in vivo MS services allow lead compound assessment in models such as the EAE, cuprizone and LPC MS models.
At Aquila, we offer CRO services to biotech and pharmaceutical companies developing treatments for a range of autoimmune diseases.
We can tailor immunology screening programs to discover the mechanisms of action (MOA) of your drug candidate for treating autoimmune disease. Such programs often involve a phenotypic screen in which specific cell types (e.g. T cells) are studied in the presence of the test compound(s).
Beyond our in vitro expertise, we offer novel, biologically relevant in vivo models of autoimmune disease, as well as off-the-shelf models for routine screening.
Our scientific team have world-leading expertise in liver fibrosis research. Leveraging their know-how, we are developing a suite of in vitro, ex vivo and in vivo assays with customisable end-points to study liver disease e.g. transition assays using primary hepatic stellate cells (HSCs) and precision cut liver slices.
At Aquila, we are scientific experts in neurodegeneration. We offer specialist discovery research services to clients looking to develop novel therapies for a range of neurodegenerative conditions.
We can tailor and develop neuroprotective screening assays to discover the mechanism of action of your drug candidate, with customised assays targeting neurons themselves and/or the supportive glial cells in isolation or co-culture.